Search Orphan Drug Designations and Approvals
-
| Generic Name: | Human autologous CD4+ and CD8+ T cells engineered ex vivo to express a T cell receptor that recognizes amino acids 11-19 of the human papillomavirus (HPV)16 E7 protein when bound to human leukocyte antigen-A*02:01 |
|---|---|
| Date Designated: | 12/01/2020 |
| Orphan Designation: | Treatment of patients with human papillomavirus (HPV)+ cervical cancer who are human leukocyte antigen (HLA)-A*02+ |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Kite Pharma, Inc. 2400 Broadway Santa Monica, California 90404 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







